Abstracts tagged "giant cell arteritis"

Abstract Number: 1883 • 2018 ACR/ARHP Annual Meeting
Infections Are Associated With Increased Risk of Giant Cell Arteritis – a Population-Based Case-Control Study From Southern Sweden
Pavlos Stamatis¹, Aleksandra Turkiewicz², Martin Englund², Goran Jönsson³, Jan-Åke Nilsson⁴, Carl Turesson⁵ and Aladdin Mohammad⁶, ¹Clinical Sciences, Rheumatology Lund, Lund University, Lund, Sweden, ²Clinical Sciences Lund, Clinical Epidemiology Unit, Lund University, Lund, Sweden, ³Clinical Sciences Lund, Department of Infection Medicine, Lund University, Lund, Sweden, ⁴Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, ⁵Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁶Rheumatology, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden
Background/Purpose: Previous studies have implicated infections as a risk factor for giant cell arteritis (GCA). The purpose of this study was to investigate the association…
Abstract Number: 2768 • 2018 ACR/ARHP Annual Meeting
Comorbidity Accrual and Mortality in an Inception Cohort of Patients with Giant Cell Arteritis and Polymyalgia Rheumatica: A Single-Center, Observational Long-Term Study
Elisheva Pokroy-Shapira¹, Ariela Dortort-Lazar^2,3 and Yair Molad^4,5, ¹Rheumatology Unit, Rabin Medical Center, Beilinson Hospital and Sackler Faculty of Medicine, Tel Aviv University, Petach Tikva, Israel, ²Rheumatology Unit, Beilinson hospital Rabin Medical Center, Petah Tikva, Israel, ³Sackler Faculty of Medicine Tel Aviv university, Tel Aviv, Israel, ⁴Rheumatology Unit, Rabin Medical Center, Beilinson Hospital, Petach Tikva, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁵Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel
Background/Purpose: Patients with giant-cell arteritis (GCA) and polymyalgia rheumatica (PMR) are treated with high cumulative glucocorticoid (GC) dose during their disease course. We sought to…
Abstract Number: 2176 • 2018 ACR/ARHP Annual Meeting
The Association of Gout with Incident Giant Cell Arteritis in Older Adults
Jasvinder A. Singh and John Cleveland, Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Giant cell arteritis (GCA) is a vasculitis that affects large and medium sized arteries in people 50 years or older. Gout, the most common…
Abstract Number: 2773 • 2018 ACR/ARHP Annual Meeting
Diagnostic and Therapeutic Management of a Suspected Case of GCA: An Opinion Survey
Henri Guillet¹, Raphaël Porcher², Alain Saraux³, Loïc Guillevin⁴, Luc Mouthon⁴ and Alexis Régent⁴, ¹Département d'aval des urgences, CHU Henri Mondor, Créteil, France, ²Université Paris Descartes Sorbonne Paris, Paris, France, ³Rheumatology, CHU Brest, Brest, France, ⁴Institut Cochin, INSERM U1016, CNRS UMR 8104, PARIS, France
Background/Purpose: Giant-cell arteritis (GCA) is the most common vasculitis. Specialists have formulated recommendations on how to manage a patient with a possible diagnosis of GCA.…
Abstract Number: 2196 • 2018 ACR/ARHP Annual Meeting
Kinetics of Tissue-Specific Distribution of 18f-Fluorodeoxyglucose in Positron Emission Tomography in Large Vessel Vasculitis
Joel S. Rosenblum¹, Kaitlin Quinn², Mark A. Ahlman³ and Peter C. Grayson⁴, ¹NIAMS, National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, ²Systemic Autoimmunity Branch, NIAMS, Bethesda, MD, ³Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, ⁴National Institute of Arthritis, Musculoskeletal and Skin Disease, National Institutes of Health, Bethesda, MD
Background/Purpose: 18F-fluorodeoxyglucose (FDG) PET may be used to quantify vascular inflammation in large-vessel vasculitis (LVV). Quantitative analysis of arterial FDG uptake has not been standardized. Delayed…
Abstract Number: 2774 • 2018 ACR/ARHP Annual Meeting
Treatment with Methotrexate and Risk of Ischemic Relapses in Patients with Giant Cell Arteritis in Clinical Practice
Judit Font Urgelles¹, Luis Rodriguez-Rodriguez², Zulema Rosales Rosado^1,2, Dalifer Freites Núñez², Leticia Leon², Inmaculada Morado¹, Esperanza Pato Cour¹, Juan A Jover Jover¹, Benjamín Fernández-Gutiérrez¹ and Lydia A Alcazar², ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain
Background/Purpose: Clinical trials have shown the efficacy of Methotrexate (MTX) in giant cell arteritis (GCA) but it is necessary to corroborate these results in real…
Abstract Number: 797 • 2017 ACR/ARHP Annual Meeting
Temporal Arteritis Revealing Antineutrophil Cytoplasmic Antibody–Associated Vasculitides: A Retrospective Study of 50 Cases
Laure Delaval^1,2, Maxime Samson³, Flora Schein⁴, Christian Agard⁵, Olivier Aumaître⁶, Alban Deroux⁷, Henry Dupuy⁸, Cyril Garrouste⁹, cedric landron¹⁰, Francois Maurier¹¹, Pascal Cathebras¹², Loïc Guillevin^2,13,14 and Benjamin Terrier^15,16,17, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, paris, France, ²Internal medicine, Cochin University Hospital, paris, France, ³Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ⁴Internal medicine, University Hospital St Etienne, Saint Etienne, France, ⁵Internal Medicine Department, Nantes University Hospital, Nantes, France, ⁶CHU Pitié-Salpêtrière - Department of Internal Medicine 2. Referal center for SLE/APS, Paris, France, ⁷Internal Medicine, CHU de Grenoble, Grenoble, France, ⁸Department of Internal Medicine, Haut-Lévêque Hospital, Pessac, France, ⁹Nephrology, CHU, Clermont-Ferrand, France, ¹⁰service de médecine interne, CH Poitiers, CHU Poitiers, poitiers, France, ¹¹Internal Medicine, Sainte-Blandine de Metz Hospital, Metz, France, ¹²Internal Medicine, University Hospital St Etienne, St Etienne, France, ¹³French Vasculitis Study Group (FVSG), Paris, France, ¹⁴National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ¹⁵Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, ¹⁶French Vasculitis Study Group (FVSG), paris, France, ¹⁷Internal Medicine, Cochin University Hospital, Paris, France
Background/Purpose: Giant cell arteritis (GCA) is a non-necrotizing granulomatous arteritis involving large vessels, whereas antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitides (AAV) are a group of necrotizing…
Abstract Number: 259 • 2017 ACR/ARHP Annual Meeting
Imaging for Diagnosis, Monitoring and Outcome Prediction of Large Vessel Vasculitis: A Systematic Review of the Literature and Meta-Analysis Informing the EULAR Recommendations
Christina Duftner¹, Christian Dejaco², Alexandre Sepriano³, Louise Falzon⁴, Wolfgang A. Schmidt⁵ and Sofia Ramiro⁶, ¹Department of Internal Medicine, Clinical Division of Internal Medicine II, Medical University Innsbruck, Innsbruck, Austria, ²Rheumatology, Hospital of Bruneck, Bruneck, Italy, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Center for Behavioral Cardiovascular Health, Columbia University Medical Center, New York, NY, ⁵Medical Center for Rheumatology and Clinical Immunology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany, ⁶Rheumatology, Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands
Background/Purpose: Modern imaging techniques including ultrasound (US), magnetic resonance imaging (MRI), computed tomography (CT) and 18F-FDG positron emission tomography (PET) are increasingly studied in large…
Abstract Number: 799 • 2017 ACR/ARHP Annual Meeting
Acetylcholinesterase Is Highly Expressed in the Inflamed Vessel Wall of Patients with Giant Cell Arteritis
Philip Therkildsen¹, Berit Dalsgaard Nielsen¹, Kresten Krarup Keller², Torben Steiniche³, Lars Christian Gormsen⁴, Ib Tønder Hansen⁵ and Ellen-Margrete Hauge⁶, ¹Department of Rheumatology, Aarhus University Hospital, Aarhus C, Denmark, ²Rheumatology, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ³Department of Histopathology, Aarhus University Hospital, Aarhus C, Denmark, ⁴Nuclear Medicine and PET Center, Department of Nuclear Medicine and PET Center, Aarhus University Hospital, Århus C, Denmark, ⁵Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁶Department of Rheumatology, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: The temporal artery biopsy (TAB) remains the gold standard in the diagnosis of giant cell arteritis (GCA). However, TABs are false-negative in 40% of…
Abstract Number: 261 • 2017 ACR/ARHP Annual Meeting
Ultrasound CUT-Off in GIANT CELL Arteritis a Solution to Arteriosclerosis Pitfall in the Halo Sign
Eugenio De Miguel¹, Luis M Beltran², Irene Monjo², Francesco Deodati², Wolfgang A. Schmidt³ and Juan García-Puig², ¹Rheumatology, University Hospital La Paz, IdiPaz, Madrid, Spain, ²Internal Medicine, Hospital Universitario La Paz, MADRID, Spain, ³Immanuel Krankenhaus Berlin, Med Ctr for Rheumatology Berlin-Buch, Berlin, Germany
Background/Purpose: At the age of Giant Cell Arteritis (GCA) atherosclerosis is common. The ultrasonographic (US) appearance of athermanous plaque is usually easily differentiated from the…
Abstract Number: 805 • 2017 ACR/ARHP Annual Meeting
Serological Immune-Inflammatory Markers of the First RCT about Tocilizumab to Treat Giant Cell Arteritis
Andrea Gloor¹, Daniel Yerly², Stefan Kuchen³, Sabine Adler⁴, Stephan Reichenbach¹, Michael Seitz⁵ and Peter M. Villiger⁶, ¹Rheumatology, University hospital, Bern, Switzerland, ²Rheumatology, Uiversity hospital, Bern, Switzerland, ³Department of Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, MD, Switzerland, ⁴Rheumatology, University Hospital Bern, Bern, Switzerland, ⁵Rheumatology, Clinical Immunology & Allergology, University Hospital, Bern, Switzerland, ⁶Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland
Background/Purpose: As published in The Lancet online, March 4, 2016, the first randomized, placebo-controlled trial (RCT) about tocilizumab (TCZ) in giant cell arteritis (GCA) showed…
Abstract Number: 778 • 2017 ACR/ARHP Annual Meeting
Safety Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations
Sara Gale¹, Sophie Dimonaco², Huong Trinh¹, Katie Tuckwell², Neil Collinson², John H. Stone³, Khaled Sarsour¹, Jinglan Pei⁴, Jennifer H. Best¹, Christine Birchwood⁴ and Shalini Mohan¹, ¹Genentech, South San Francisco, CA, ²Roche Products, Ltd., Welwyn Garden City, United Kingdom, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁴Genentech, Inc., South San Francisco, CA
Background/Purpose: Recent clinical trial findings have shown efficacy for tocilizumab (TCZ) in treating giant cell arteritis (GCA).1,2 TCZ was approved for the treatment of GCA…
Abstract Number: 806 • 2017 ACR/ARHP Annual Meeting
Epidemiological Study of Giant Cell Arteritis Using a Japanese Administrative Database
Eishi Uechi and Kiyohide Fushimi, Department of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School, Tokyo, Japan
Background/Purpose: The giant cell arteritis (GCA) management requires the administration of high-dose glucocorticoid (GC) at the introduction remission and the gradual reduction of the dosage.…
Abstract Number: 779 • 2017 ACR/ARHP Annual Meeting
Assessment of Treatment Response By 18f-Fludeoxyglucose Positron Emission Tomography (FDG-PET) in Patients with Large Vessel Vasculitis (LVV)
Shubhasree Banerjee¹, Sara Alehashemi², Ali Cahid Civelek³, Elaine Novakovich⁴, Armin Bagheri⁵, Ashkan Malayeri³, Mark Ahlman³ and Peter C. Grayson⁶, ¹Fellowship and training branch, NIAMS/NIH, Bethesda, MD, ²Rheumatology, National Institutes of Health, Bethesda, MD, ³Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, ⁴Systemic Autoimmunity Branch, NIAMS, National Institutes of Health, Bethesda, MD, ⁵Vasculitis Translational Research Program, NIAMS, NIH, Bethesda, MD, ⁶Research, National Institutes of Health, Bethesda, MD
Background/Purpose: Disease activity in large vessel vasculitis (LVV) is traditionally assessed by clinical and serological (ESR, CRP) parameters. Imaging assessment, including FDG-PET, may also be…
Abstract Number: 808 • 2017 ACR/ARHP Annual Meeting
Assessing the Possible Link between Varicella Zoster Virus and Giant Cell Arteritis Using Clinical Assessment, Serology and Biopsy Antigen Detection – Interim Results from the Giant Cell Arteritis and PET Scan (GAPS) Cohort
Anthony Sammel¹, Katherine Nguyen², Susan Smith³, Christopher Little³, Janice Brewer² and Rodger Laurent², ¹Rheumatology, Royal North Shore Hospital, St Leonards, Sydney, Australia, ²Royal North Shore Hospital, St Leonards, Sydney, Australia, ³Raymond Purves Bone and Joint Research Laboratories, Kolling Institute, Sydney, Australia
Background/Purpose: Recent studies have suggested that giant cell arteritis (GCA) may be triggered by reactivation of varicella zoster virus (VZV) based on high rates of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].